Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded NK Cells for CMV Prevention Post-Haploidentical HSCT
NCT04320303Phase 1Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of membrane-bound interleukin-21/4-1BB ligand-expanded natural killer cells in cytomegalovirus infection (CMV), sponsored by Peking University People's Hospital. Primary endpoint: Cumulative incidence of CMV infection post transplantation at 180 days. Status: unknown.
02
Drugs
membrane-bound interleukin-21/4-1BB ligand-expanded natural killer cells
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04320303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320303.